Champions Oncology (CSBR) EBIAT (2016 - 2026)
Champions Oncology has reported EBIAT over the past 17 years, most recently at -$279000.0 for Q1 2026.
- Quarterly results put EBIAT at -$279000.0 for Q1 2026, down 106.21% from a year ago — trailing twelve months through Jan 2026 was -$2.3 million (down 135.99% YoY), and the annual figure for FY2025 was $4.7 million, up 164.6%.
- EBIAT for Q1 2026 was -$279000.0 at Champions Oncology, down from $268000.0 in the prior quarter.
- Over the last five years, EBIAT for CSBR hit a ceiling of $4.5 million in Q1 2025 and a floor of -$2.6 million in Q3 2023.
- Median EBIAT over the past 5 years was -$319000.0 (2022), compared with a mean of -$467352.9.
- Biggest five-year swings in EBIAT: tumbled 12843.75% in 2023 and later soared 277.67% in 2025.
- Champions Oncology's EBIAT stood at -$16000.0 in 2022, then tumbled by 12843.75% to -$2.1 million in 2023, then skyrocketed by 135.15% to $728000.0 in 2024, then plummeted by 63.19% to $268000.0 in 2025, then tumbled by 204.1% to -$279000.0 in 2026.
- The last three reported values for EBIAT were -$279000.0 (Q1 2026), $268000.0 (Q4 2025), and -$466000.0 (Q3 2025) per Business Quant data.